Preliminary clinical evaluation of 1, 2-bis(beta-chloroethylthylthio) ethane (SM-1) in patients with advanced lymphomas and neoplastic diseases.
D000970:Antineoplastic Agents; D004980:Ethane; D008223:Lymphoma / Q000628:therapy*; D008466:Mechlorethamine; D009151:Mustard Gas / Q000627:therapeutic use*; D009219:Myosin-Light-Chain Kinase; D009369:Neoplasms; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D010446:Peptide Fragments
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D010446:Peptide Fragments; C090954:SM 1 peptide; D008466:Mechlorethamine; D009219:Myosin-Light-Chain Kinase; D004980:Ethane; D009151:Mustard Gas
CYTOTOXIC DRUGS; LYMPHOMA/therapy; MUSTARD GAS/therapeutic use; NITROGEN MUSTARDS/therapeutic use